<DOC>
	<DOCNO>NCT01228565</DOCNO>
	<brief_summary>The aim randomize trial compare rate radio-dermatitis grade 2+ ( NCI-CTC V3.0 ) patient receive radiotherapy+Erbitux+placebo versus patient receive radiotherapy+Erbitux+OTD70DERM® treatment head neck carcinoma .</brief_summary>
	<brief_title>Trial OTD70DERM® Radio-dermatitis Induced Radiotherapy-Erbitux®</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Head neck carcinoma treat radiotherapy ( 70Gy ) plus Erbitux IMRT ; Concomitant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Head neck carcinoma treat radiotherapy plus erbitux</keyword>
</DOC>